A new study has found faster accumulation of tau -- a key indicator of Alzheimer's disease -- in the brains of women over the age of 70 who took menopausal hormone therapy (HT) more than a decade ...

Through his X handler, Kamath revealed that he has been following the developments around Ozempic and GLP-1 drugs with some ...

Shares of Cassava Sciences SAVA plunged 32.1% on Tuesday after the company announced that its lead pipeline candidate, ...

President Donald Trump continues to warn of tariffs on the pharmaceutical industry; Susan Monarez replaces Dave Weldon as CDC ...

A clinical trial involving individuals genetically predisposed to develop early-onset Alzheimer’s disease suggests that ...

The company ended 2024 with just under $127 million in cash reserves, and nothing in its pipeline beyond the Alzheimer's ...

Investing in stocks remains one of the best ways to accumulate capital over long periods. Companies that can last -- and ...

Several ASX healthcare companies are leading the charge in finding new treatments for complex neurological disorders.

Zerodha CEO Nithin Kamath described weight-loss drugs Ozempic and Mounjaro as near 'miracle drugs,' highlighting their ...

The British pharmaceutical giant is working with the U.K. Dementia Research Institute to exploit a “natural randomization” ...

Merck has signed a licensing deal with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion for its experimental heart ...

After multiple studies have suggested a link between its shingles vaccine and dementia prevention, GSK is taking advantage of ...